Over Three Years after Receiving a Complete Response Letter From the FDA, Takeda’s Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights

An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. EXTON, Pa., May 4, 2023 /PRNewswire/ — In December 2019, Takeda Pharmaceutical Company (“Takeda”) announced the receipt of a complete response letter (CRL) for the subcutaneous (SC)…